Polycystic ovary syndrome and infertility | EWS | REWIND

This session focuses on the major 2023 shift in international polycystic ovary syndrome (PCOS) guidance, which emphasises the condition’s metabolic underpinnings and evolving definitions. We will update you on how genotype and phenotype distinctions shape management strategies, the significance of  anti-müllerian hormone (AMH) testing, and how new injectable fertility treatments are transforming outcomes for patients with PCOS. The session blends endocrine nuance with practical treatment tips to improve fertility care in real life.

Learning Objectives: 

• PCOS phenotype vs genotype: what it means in the clinic.
• AMH and egg count: how to interpret and use.
• Metabolic syndrome and long-term health.
• Injectables in PCOS fertility treatment: what's changed and why it matters.